

Systemic Therapy Education Bulletin

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration



The goal of the Education Bulletin is to support health care staff as they prepare for new treatments and to ensure safe patient care during the administration, distribution and management of new and complex treatments. These new drug treatments may also be delivered to patients prior to formal listing through manufacturer patient support programs or clinical trials. Full details around the funded indications and eligibility criteria will be available in the Protocol Summaries and summarized in the Systemic Therapy Update newsletter once funding decisions have been finalized. More details about the drugs, approved indications, and side effects can be found in the BC Cancer drug monographs, accessible from the Cancer Drug Manual [Drug Index](#).

UGILEN

Treatment Programs	Indication: Under Review (Refer to protocol for more details)	Associated Adverse Events
Lenvatinib	Treatment of patients with advanced Hepatocellular Carcinoma (HCC)	Possible adverse events (of any grade): <ul style="list-style-type: none"> • Posterior Reversible Encephalopathy Syndrome (PRES) • QT prolongation • Hypertension • Diarrhea • Fatigue • Nausea • Decreased appetite • Weight loss • Palmar-plantar erythrodysesthesia (PPE) • Renal toxicity • Proteinuria • Hemorrhage • Hepatotoxicity

Dosing and Administration Information

Pre-medications:

- **Antiemetic:** low to moderate emetogenicity (see [SCNAUSEA](#))

Dosing and Schedule: One cycle = 30 days

- Weight less than 60 kg:
 - **Oral lenvatinib** 8 mg once daily with or without food until toxicity or disease progression.
- Weight great than or equal to 60 kg:
 - **Oral lenvatinib** 12 mg once daily with or without food until toxicity or disease progression.

Additional Protocol Information:

- It is recommended that for at least the first 2 cycles of treatment patients monitor their blood pressure daily (home measurements, GP's office, etc.) and keep a journal of their blood pressure measurements that can be submitted to the provider.

UGINFOCLAR

Treatment Programs	Indication (Refer to protocol for more details)	Associated Adverse Events
Octreotide (SANDOSTATIN LAR®)	Management of Non-Functional Neuroendocrine Tumours of the GI Tract	Possible adverse events: <ul style="list-style-type: none"> • Bradycardia • Arrhythmia • GI symptoms <ul style="list-style-type: none"> ○ Diarrhea ○ Abnormal stools • Biliary tract abnormalities <ul style="list-style-type: none"> ○ Gallstones • Injection site reactions • Hyperglycemia
Dosing and Administration Information		
Premedications: <ul style="list-style-type: none"> • Not needed 		
Dosing and Schedule: <ul style="list-style-type: none"> • IM octreotide 30 mg every 4 weeks until tumour progression or intolerable toxicity 		
Additional Protocol Information: <ul style="list-style-type: none"> • May use quadriceps for self-administration 		

LUAVCRIZR

Treatment Programs	Indication (Refer to protocol for more details)	Associated Adverse Events
Crizotinib	Treatment of patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)	Possible adverse events: <ul style="list-style-type: none"> • Neutropenia • Hypophosphatemia • Hepatotoxicity • Visual disorders • Nausea • Vomiting • Diarrhea • Constipation • Peripheral edema • Cardiotoxicity <ul style="list-style-type: none"> ○ QT prolongation ○ Bradycardia • Pneumonitis
Dosing and Administration Information		
Premedications: <ul style="list-style-type: none"> • Not needed 		
Dosing and Schedule: <ul style="list-style-type: none"> • Oral crizotinib 250 mg twice daily with or without food until toxicity or disease progression. 		

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe or update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca
Systemic Therapy Education Bulletin: http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/education-bulletin	